[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
April 11, 2007

Researchers Buoyed by Novel HIV Drugs

JAMA. 2007;297(14):1535-1536. doi:10.1001/jama.297.14.1535

Los Angeles—Two investigational drugs that take aim at novel therapeutic targets show promise for treating patients infected with HIV strains that are resistant to existing drugs, according to findings presented here at the 14th Annual Conference on Retroviruses and Opportunistic Infections.

The data, from large efficacy trials, indicate that drug combinations containing the new medications achieved substantial levels of viral suppression in extensively treated patients with drug-resistant HIV. The response of patients was analogous to that seen when highly active antiretroviral therapy first became available, said John Mellors, MD, of the University of Pittsburgh School of Medicine at a press briefing about the new findings. “It's really a remarkable development in the field,” added Mellors, who was vice chair of the conference's scientific program committee.